News
Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...
20h
WISH-TV on MSNEurope grants limited approval to Lilly's Alzheimer's drugEurope has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...
Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...
Explore more
20h
GlobalData on MSNRoche’s Alzheimer’s therapy shows continued benefitRoche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...
A clinical trial of the drug Trontinemab will aim to delay or prevent the symptoms of Alzheimer's disease, Swiss drugmaker Roche says.
Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...
The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results